Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiotherapy Planning, Computer-Assisted | 38 | 2020 | 1661 | 1.840 |
Why?
|
Radiotherapy Dosage | 58 | 2023 | 2898 | 1.490 |
Why?
|
Radiation Injuries | 22 | 2020 | 1189 | 1.200 |
Why?
|
Radiosurgery | 14 | 2021 | 1342 | 0.950 |
Why?
|
Linear Energy Transfer | 5 | 2020 | 152 | 0.940 |
Why?
|
Radiotherapy, Adjuvant | 22 | 2020 | 1784 | 0.740 |
Why?
|
Neoplasm Recurrence, Local | 30 | 2023 | 9275 | 0.670 |
Why?
|
Photons | 14 | 2023 | 589 | 0.670 |
Why?
|
Breast Neoplasms | 40 | 2024 | 21009 | 0.670 |
Why?
|
Cranial Irradiation | 6 | 2020 | 390 | 0.650 |
Why?
|
Necrosis | 5 | 2020 | 1605 | 0.650 |
Why?
|
Organs at Risk | 8 | 2020 | 359 | 0.640 |
Why?
|
Radiotherapy, Conformal | 12 | 2018 | 548 | 0.630 |
Why?
|
Meningioma | 9 | 2020 | 1218 | 0.610 |
Why?
|
Radiation Tolerance | 12 | 2020 | 479 | 0.600 |
Why?
|
Dose-Response Relationship, Radiation | 21 | 2019 | 882 | 0.580 |
Why?
|
Brain Neoplasms | 20 | 2020 | 9030 | 0.560 |
Why?
|
Chordoma | 8 | 2023 | 346 | 0.540 |
Why?
|
Urinary Bladder Neoplasms | 8 | 2023 | 2210 | 0.470 |
Why?
|
Protons | 12 | 2023 | 1115 | 0.450 |
Why?
|
Cystectomy | 7 | 2023 | 634 | 0.450 |
Why?
|
Radiotherapy, Intensity-Modulated | 8 | 2018 | 801 | 0.430 |
Why?
|
Radiotherapy | 7 | 2019 | 1499 | 0.410 |
Why?
|
Neoplasms, Second Primary | 6 | 2023 | 1051 | 0.410 |
Why?
|
Meningeal Neoplasms | 6 | 2019 | 1248 | 0.400 |
Why?
|
Radiation Oncology | 6 | 2022 | 563 | 0.400 |
Why?
|
Spinal Cord | 7 | 2019 | 1817 | 0.340 |
Why?
|
Models, Biological | 21 | 2020 | 9468 | 0.340 |
Why?
|
Tumor Burden | 12 | 2019 | 1887 | 0.340 |
Why?
|
Mastectomy, Segmental | 10 | 2015 | 953 | 0.330 |
Why?
|
Retrospective Studies | 67 | 2023 | 80575 | 0.320 |
Why?
|
Neoadjuvant Therapy | 8 | 2020 | 2823 | 0.320 |
Why?
|
Neoplasms, Radiation-Induced | 6 | 2012 | 549 | 0.320 |
Why?
|
Pancreatic Neoplasms | 8 | 2023 | 5363 | 0.320 |
Why?
|
Relative Biological Effectiveness | 8 | 2019 | 312 | 0.320 |
Why?
|
Prostatic Neoplasms | 16 | 2022 | 11116 | 0.320 |
Why?
|
Intracranial Arteriovenous Malformations | 3 | 2020 | 366 | 0.310 |
Why?
|
Systems Biology | 4 | 2014 | 481 | 0.300 |
Why?
|
Middle Aged | 109 | 2024 | 220774 | 0.300 |
Why?
|
Neoplasm Staging | 24 | 2023 | 11098 | 0.300 |
Why?
|
Aged | 97 | 2024 | 169179 | 0.300 |
Why?
|
Anus Neoplasms | 3 | 2017 | 329 | 0.300 |
Why?
|
Seminoma | 2 | 2023 | 134 | 0.300 |
Why?
|
Radiation Pneumonitis | 3 | 2018 | 102 | 0.290 |
Why?
|
Radiation Dosage | 6 | 2018 | 1958 | 0.280 |
Why?
|
Humans | 192 | 2024 | 761326 | 0.270 |
Why?
|
Mastectomy | 8 | 2020 | 1822 | 0.270 |
Why?
|
Female | 128 | 2024 | 392485 | 0.270 |
Why?
|
Disease-Free Survival | 18 | 2022 | 6815 | 0.270 |
Why?
|
Chondrosarcoma | 3 | 2023 | 296 | 0.270 |
Why?
|
Kaplan-Meier Estimate | 17 | 2020 | 6473 | 0.260 |
Why?
|
Neoplasms | 19 | 2021 | 22158 | 0.250 |
Why?
|
Combined Modality Therapy | 18 | 2022 | 8526 | 0.240 |
Why?
|
Follow-Up Studies | 35 | 2023 | 39108 | 0.240 |
Why?
|
Radiotherapy, Computer-Assisted | 3 | 1989 | 90 | 0.240 |
Why?
|
Aged, 80 and over | 46 | 2024 | 58946 | 0.230 |
Why?
|
Neuroma, Acoustic | 2 | 2021 | 459 | 0.230 |
Why?
|
Nomograms | 3 | 2013 | 228 | 0.230 |
Why?
|
Adult | 82 | 2024 | 221122 | 0.230 |
Why?
|
Skull Base Neoplasms | 3 | 2023 | 270 | 0.230 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 491 | 0.230 |
Why?
|
Male | 100 | 2023 | 360621 | 0.230 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2021 | 11735 | 0.230 |
Why?
|
Cerebellar Neoplasms | 2 | 2022 | 586 | 0.230 |
Why?
|
Lung Neoplasms | 13 | 2020 | 13333 | 0.230 |
Why?
|
Medulloblastoma | 2 | 2022 | 678 | 0.220 |
Why?
|
Sarcoma | 4 | 2017 | 1793 | 0.220 |
Why?
|
Retroperitoneal Neoplasms | 3 | 2017 | 332 | 0.220 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 7 | 2020 | 5303 | 0.220 |
Why?
|
Hospitals, General | 4 | 2017 | 798 | 0.220 |
Why?
|
Disease Progression | 18 | 2023 | 13500 | 0.220 |
Why?
|
Liver Neoplasms | 6 | 2021 | 4321 | 0.210 |
Why?
|
Neoplasm Invasiveness | 13 | 2021 | 3588 | 0.210 |
Why?
|
Watchful Waiting | 2 | 2020 | 491 | 0.210 |
Why?
|
Treatment Outcome | 42 | 2023 | 64645 | 0.210 |
Why?
|
Testicular Neoplasms | 2 | 2023 | 799 | 0.210 |
Why?
|
Adenocarcinoma | 6 | 2023 | 6332 | 0.200 |
Why?
|
Spinal Neoplasms | 4 | 2016 | 716 | 0.200 |
Why?
|
Tissue Expansion Devices | 2 | 2020 | 156 | 0.200 |
Why?
|
Mammaplasty | 3 | 2020 | 1239 | 0.200 |
Why?
|
Quality of Life | 8 | 2024 | 13355 | 0.190 |
Why?
|
Volition | 1 | 2021 | 62 | 0.190 |
Why?
|
Dangerous Behavior | 1 | 2021 | 65 | 0.190 |
Why?
|
Spinal Cord Neoplasms | 2 | 2016 | 263 | 0.190 |
Why?
|
Probability | 8 | 2020 | 2478 | 0.180 |
Why?
|
Nerve Tissue | 1 | 2021 | 78 | 0.180 |
Why?
|
Brain | 7 | 2020 | 27103 | 0.180 |
Why?
|
Pituitary Gland | 3 | 2019 | 635 | 0.180 |
Why?
|
Salvage Therapy | 5 | 2018 | 1264 | 0.180 |
Why?
|
Prognosis | 20 | 2021 | 29588 | 0.180 |
Why?
|
Law Enforcement | 1 | 2021 | 112 | 0.170 |
Why?
|
Paraganglioma, Extra-Adrenal | 1 | 2019 | 45 | 0.170 |
Why?
|
Polyploidy | 5 | 1985 | 119 | 0.170 |
Why?
|
Proportional Hazards Models | 17 | 2021 | 12450 | 0.170 |
Why?
|
Respiration | 3 | 2013 | 1657 | 0.170 |
Why?
|
Bone Neoplasms | 3 | 2019 | 2527 | 0.160 |
Why?
|
Hypopituitarism | 2 | 2019 | 250 | 0.160 |
Why?
|
Breast Implants | 2 | 2020 | 411 | 0.160 |
Why?
|
Neoplasm, Residual | 5 | 2015 | 1008 | 0.160 |
Why?
|
Endometrial Neoplasms | 2 | 2022 | 1365 | 0.160 |
Why?
|
DNA Mismatch Repair | 1 | 2022 | 428 | 0.160 |
Why?
|
Head and Neck Neoplasms | 5 | 2019 | 2891 | 0.160 |
Why?
|
Cytochalasin B | 5 | 1985 | 74 | 0.160 |
Why?
|
Carcinoma | 3 | 2017 | 2328 | 0.150 |
Why?
|
Carcinoma, Lobular | 3 | 2013 | 481 | 0.150 |
Why?
|
Carcinoma in Situ | 3 | 2013 | 791 | 0.150 |
Why?
|
Brachytherapy | 3 | 2022 | 1223 | 0.150 |
Why?
|
Neurocytoma | 1 | 2018 | 29 | 0.150 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 256 | 0.150 |
Why?
|
Sentinel Lymph Node Biopsy | 3 | 2008 | 732 | 0.150 |
Why?
|
Mathematical Computing | 3 | 1998 | 142 | 0.150 |
Why?
|
Tetradecanoylphorbol Acetate | 2 | 1992 | 818 | 0.150 |
Why?
|
Protein Kinase Inhibitors | 4 | 2023 | 5665 | 0.150 |
Why?
|
Receptor, erbB-2 | 5 | 2018 | 2556 | 0.150 |
Why?
|
Oocytes | 4 | 1992 | 1166 | 0.150 |
Why?
|
Glioma | 3 | 2019 | 3455 | 0.150 |
Why?
|
Computational Biology | 4 | 2021 | 3512 | 0.150 |
Why?
|
Young Adult | 29 | 2023 | 59196 | 0.150 |
Why?
|
Endpoint Determination | 1 | 2020 | 590 | 0.150 |
Why?
|
Spinal Cord Diseases | 2 | 2019 | 293 | 0.150 |
Why?
|
Time Factors | 22 | 2021 | 39974 | 0.150 |
Why?
|
Emergency Treatment | 1 | 2021 | 496 | 0.150 |
Why?
|
Radiometry | 5 | 2018 | 813 | 0.140 |
Why?
|
Neoplasm Metastasis | 7 | 2024 | 4908 | 0.140 |
Why?
|
Optic Nerve | 2 | 2018 | 572 | 0.140 |
Why?
|
Chondrosarcoma, Mesenchymal | 1 | 2016 | 12 | 0.140 |
Why?
|
Pelvic Bones | 2 | 2017 | 270 | 0.140 |
Why?
|
Lymphatic Irradiation | 4 | 2010 | 115 | 0.140 |
Why?
|
Postoperative Care | 3 | 2019 | 1471 | 0.140 |
Why?
|
Breast Implantation | 1 | 2019 | 223 | 0.140 |
Why?
|
Lymph Nodes | 5 | 2022 | 3469 | 0.140 |
Why?
|
Survival Rate | 12 | 2019 | 12710 | 0.130 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2023 | 781 | 0.130 |
Why?
|
Peritoneum | 1 | 2017 | 225 | 0.130 |
Why?
|
Hippocampus | 2 | 2020 | 3763 | 0.130 |
Why?
|
Cholecystitis | 1 | 2017 | 181 | 0.130 |
Why?
|
Treatment Failure | 6 | 2019 | 2642 | 0.130 |
Why?
|
Scattering, Radiation | 1 | 2017 | 490 | 0.130 |
Why?
|
Prostatectomy | 3 | 2018 | 1824 | 0.130 |
Why?
|
Adolescent | 29 | 2023 | 88305 | 0.130 |
Why?
|
Research Report | 3 | 2019 | 367 | 0.130 |
Why?
|
Lymph Node Excision | 6 | 2020 | 1273 | 0.130 |
Why?
|
Postoperative Period | 5 | 2020 | 1813 | 0.130 |
Why?
|
Carcinoma, Ductal, Breast | 4 | 2010 | 1085 | 0.130 |
Why?
|
Gallbladder | 1 | 2017 | 308 | 0.120 |
Why?
|
BRCA2 Protein | 1 | 2020 | 804 | 0.120 |
Why?
|
Fluorodeoxyglucose F18 | 4 | 2018 | 2009 | 0.120 |
Why?
|
Chemotherapy, Adjuvant | 9 | 2016 | 3512 | 0.120 |
Why?
|
Estrogen Receptor alpha | 1 | 2019 | 581 | 0.120 |
Why?
|
Cobalt Radioisotopes | 3 | 1989 | 75 | 0.120 |
Why?
|
Optic Nerve Diseases | 1 | 2018 | 342 | 0.120 |
Why?
|
Bone Marrow Diseases | 1 | 2017 | 233 | 0.120 |
Why?
|
Waiting Lists | 1 | 2019 | 765 | 0.120 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2018 | 617 | 0.120 |
Why?
|
Urothelium | 1 | 2016 | 269 | 0.120 |
Why?
|
Neutropenia | 2 | 2017 | 884 | 0.120 |
Why?
|
Sacrum | 1 | 2016 | 276 | 0.120 |
Why?
|
Gene Regulatory Networks | 2 | 2014 | 1741 | 0.120 |
Why?
|
Respiratory Function Tests | 1 | 1999 | 1682 | 0.120 |
Why?
|
Minority Groups | 1 | 2022 | 1203 | 0.120 |
Why?
|
Rhabdomyosarcoma, Embryonal | 1 | 2015 | 100 | 0.120 |
Why?
|
Pituitary Neoplasms | 2 | 2014 | 1324 | 0.120 |
Why?
|
Faculty, Medical | 2 | 2022 | 1202 | 0.110 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2019 | 2299 | 0.110 |
Why?
|
Prostate-Specific Antigen | 2 | 2022 | 2469 | 0.110 |
Why?
|
Models, Theoretical | 5 | 2020 | 3577 | 0.110 |
Why?
|
Medical Oncology | 4 | 2022 | 2321 | 0.110 |
Why?
|
Community Health Centers | 1 | 2017 | 461 | 0.110 |
Why?
|
Vagina | 2 | 2022 | 838 | 0.110 |
Why?
|
Multivariate Analysis | 10 | 2018 | 12059 | 0.110 |
Why?
|
Analysis of Variance | 11 | 2014 | 6231 | 0.110 |
Why?
|
Genetic Research | 1 | 2014 | 171 | 0.110 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2019 | 2911 | 0.110 |
Why?
|
Gene Expression Profiling | 3 | 2021 | 9414 | 0.110 |
Why?
|
BRCA1 Protein | 1 | 2020 | 1155 | 0.110 |
Why?
|
Quality Assurance, Health Care | 1 | 2004 | 2170 | 0.110 |
Why?
|
Uncertainty | 1 | 2018 | 754 | 0.110 |
Why?
|
Genomics | 4 | 2018 | 5817 | 0.110 |
Why?
|
Software | 1 | 2007 | 4439 | 0.110 |
Why?
|
Pelvis | 1 | 2017 | 732 | 0.110 |
Why?
|
Hypothalamus | 1 | 2018 | 999 | 0.110 |
Why?
|
Lung Injury | 1 | 2018 | 422 | 0.110 |
Why?
|
Nephrectomy | 2 | 2015 | 936 | 0.110 |
Why?
|
Germinoma | 1 | 2013 | 132 | 0.100 |
Why?
|
Urinary Bladder | 2 | 2023 | 1150 | 0.100 |
Why?
|
Blood Vessels | 1 | 2018 | 1113 | 0.100 |
Why?
|
Cell Survival | 3 | 2010 | 5792 | 0.100 |
Why?
|
Puromycin | 1 | 1992 | 42 | 0.100 |
Why?
|
Adenoma | 2 | 2014 | 2159 | 0.100 |
Why?
|
Health Physics | 1 | 2012 | 32 | 0.100 |
Why?
|
Abdominal Neoplasms | 1 | 2013 | 287 | 0.100 |
Why?
|
Safety Management | 1 | 2017 | 760 | 0.100 |
Why?
|
Risk Factors | 23 | 2019 | 74152 | 0.100 |
Why?
|
Propensity Score | 4 | 2023 | 1908 | 0.100 |
Why?
|
Radiotherapy, High-Energy | 2 | 1989 | 228 | 0.100 |
Why?
|
Uveal Neoplasms | 1 | 2014 | 341 | 0.090 |
Why?
|
Tumor Cells, Cultured | 2 | 2002 | 6128 | 0.090 |
Why?
|
Movement | 2 | 2009 | 1478 | 0.090 |
Why?
|
Patient Selection | 3 | 2014 | 4244 | 0.090 |
Why?
|
Image Processing, Computer-Assisted | 4 | 2018 | 8997 | 0.090 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 1 | 2011 | 146 | 0.090 |
Why?
|
Neuroblastoma | 1 | 2019 | 1250 | 0.090 |
Why?
|
Constriction, Pathologic | 1 | 2014 | 1097 | 0.090 |
Why?
|
Mathematics | 4 | 2001 | 707 | 0.090 |
Why?
|
Societies, Scientific | 1 | 2012 | 222 | 0.090 |
Why?
|
Survival Analysis | 6 | 2020 | 10075 | 0.090 |
Why?
|
Memory Disorders | 1 | 2018 | 1198 | 0.090 |
Why?
|
Ovum | 2 | 1985 | 187 | 0.090 |
Why?
|
Neurofibromatosis 2 | 1 | 2014 | 385 | 0.090 |
Why?
|
Alcoholism | 1 | 2021 | 1973 | 0.090 |
Why?
|
Receptors, Progesterone | 3 | 2012 | 1129 | 0.090 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 276 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 2060 | 0.090 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2015 | 1246 | 0.090 |
Why?
|
Program Evaluation | 1 | 2018 | 2494 | 0.090 |
Why?
|
Positron-Emission Tomography | 3 | 2018 | 6478 | 0.090 |
Why?
|
Lymphoma | 1 | 1999 | 1901 | 0.090 |
Why?
|
Esophageal Neoplasms | 2 | 2011 | 1647 | 0.090 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2010 | 350 | 0.090 |
Why?
|
Lymphedema | 2 | 2013 | 525 | 0.090 |
Why?
|
Esophagus | 1 | 2016 | 1030 | 0.080 |
Why?
|
Bone Marrow | 3 | 2017 | 2909 | 0.080 |
Why?
|
Data Collection | 3 | 2022 | 3324 | 0.080 |
Why?
|
Lymphatic Metastasis | 8 | 2011 | 2914 | 0.080 |
Why?
|
Embolization, Therapeutic | 1 | 2019 | 1418 | 0.080 |
Why?
|
Biophysical Phenomena | 3 | 1995 | 320 | 0.080 |
Why?
|
Thrombosis | 1 | 2023 | 2942 | 0.080 |
Why?
|
Delayed Diagnosis | 1 | 2013 | 462 | 0.080 |
Why?
|
Paclitaxel | 3 | 2013 | 1732 | 0.080 |
Why?
|
Carcinoma, Renal Cell | 2 | 2014 | 3161 | 0.080 |
Why?
|
Survivors | 2 | 2017 | 2370 | 0.080 |
Why?
|
ras Proteins | 1 | 2014 | 1053 | 0.080 |
Why?
|
Urologic Surgical Procedures | 1 | 2011 | 298 | 0.080 |
Why?
|
Biophysics | 3 | 1995 | 380 | 0.080 |
Why?
|
Oligodendroglioma | 1 | 2010 | 279 | 0.080 |
Why?
|
Receptors, Estrogen | 4 | 2012 | 2208 | 0.080 |
Why?
|
Occupational Exposure | 2 | 2017 | 1813 | 0.080 |
Why?
|
Child, Preschool | 12 | 2023 | 42251 | 0.080 |
Why?
|
Child | 18 | 2023 | 80156 | 0.080 |
Why?
|
Physics | 1 | 2008 | 91 | 0.080 |
Why?
|
Azacitidine | 1 | 2010 | 336 | 0.080 |
Why?
|
Hodgkin Disease | 2 | 2009 | 1378 | 0.080 |
Why?
|
Cholangiocarcinoma | 1 | 2013 | 552 | 0.080 |
Why?
|
Probability Theory | 1 | 2007 | 11 | 0.080 |
Why?
|
Bile Duct Neoplasms | 1 | 2013 | 605 | 0.080 |
Why?
|
Massachusetts | 6 | 2021 | 8837 | 0.070 |
Why?
|
Zygote | 2 | 1981 | 115 | 0.070 |
Why?
|
Melanoma | 2 | 2018 | 5706 | 0.070 |
Why?
|
Algorithms | 9 | 2007 | 14025 | 0.070 |
Why?
|
Kidney Neoplasms | 2 | 2014 | 4246 | 0.070 |
Why?
|
Mastectomy, Modified Radical | 2 | 2009 | 62 | 0.070 |
Why?
|
Postoperative Complications | 4 | 2019 | 15647 | 0.070 |
Why?
|
Risk | 7 | 2013 | 9605 | 0.070 |
Why?
|
Ependymoma | 1 | 2010 | 320 | 0.070 |
Why?
|
Incidence | 8 | 2020 | 21336 | 0.070 |
Why?
|
Colorectal Neoplasms | 3 | 2020 | 6901 | 0.070 |
Why?
|
Cell Cycle Proteins | 1 | 2019 | 3448 | 0.070 |
Why?
|
Databases, Factual | 3 | 2019 | 7954 | 0.070 |
Why?
|
Risk Assessment | 11 | 2019 | 23981 | 0.070 |
Why?
|
Patient Satisfaction | 1 | 2019 | 3460 | 0.070 |
Why?
|
Epidemiologic Studies | 1 | 2010 | 674 | 0.070 |
Why?
|
Thoracic Wall | 1 | 2009 | 202 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1624 | 0.070 |
Why?
|
Mice, Inbred A | 3 | 1981 | 246 | 0.070 |
Why?
|
Catechin | 1 | 2007 | 69 | 0.070 |
Why?
|
Axilla | 4 | 2013 | 624 | 0.070 |
Why?
|
Interdisciplinary Communication | 1 | 2012 | 931 | 0.070 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 7999 | 0.070 |
Why?
|
Internet | 2 | 2010 | 3094 | 0.070 |
Why?
|
Carbon | 1 | 2010 | 665 | 0.070 |
Why?
|
Embryo, Mammalian | 3 | 2001 | 1675 | 0.070 |
Why?
|
Referral and Consultation | 3 | 2014 | 3597 | 0.070 |
Why?
|
Phorbols | 1 | 1985 | 43 | 0.070 |
Why?
|
Astrocytoma | 1 | 2010 | 775 | 0.060 |
Why?
|
Cohort Studies | 10 | 2021 | 41440 | 0.060 |
Why?
|
Fluorouracil | 3 | 2017 | 1637 | 0.060 |
Why?
|
Mutation | 6 | 2021 | 30044 | 0.060 |
Why?
|
Mitomycin | 2 | 2017 | 263 | 0.060 |
Why?
|
Neuroendocrine Tumors | 1 | 2012 | 642 | 0.060 |
Why?
|
Laparoscopy | 1 | 2017 | 2035 | 0.060 |
Why?
|
Zona Pellucida | 1 | 1985 | 14 | 0.060 |
Why?
|
Cauda Equina | 1 | 2005 | 45 | 0.060 |
Why?
|
Muscles | 2 | 2023 | 1575 | 0.060 |
Why?
|
Osteosarcoma | 1 | 2011 | 896 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2023 | 5841 | 0.060 |
Why?
|
Skull Neoplasms | 2 | 2018 | 173 | 0.060 |
Why?
|
Microtubule-Associated Proteins | 1 | 2010 | 1075 | 0.060 |
Why?
|
Substance-Related Disorders | 1 | 2021 | 4419 | 0.060 |
Why?
|
Medical Records Systems, Computerized | 1 | 2010 | 1192 | 0.060 |
Why?
|
Ki-67 Antigen | 2 | 2017 | 629 | 0.060 |
Why?
|
Actuarial Analysis | 2 | 2019 | 374 | 0.060 |
Why?
|
Regression Analysis | 4 | 2016 | 6341 | 0.060 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2011 | 2897 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5439 | 0.060 |
Why?
|
Prospective Studies | 10 | 2019 | 54405 | 0.060 |
Why?
|
Boston | 5 | 2017 | 9333 | 0.060 |
Why?
|
Monte Carlo Method | 3 | 2014 | 1257 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2013 | 2221 | 0.050 |
Why?
|
Age Factors | 6 | 2017 | 18401 | 0.050 |
Why?
|
Mesenteric Veins | 1 | 2023 | 86 | 0.050 |
Why?
|
Urination Disorders | 2 | 2016 | 238 | 0.050 |
Why?
|
Kidney Failure, Chronic | 1 | 2015 | 2471 | 0.050 |
Why?
|
Recurrence | 4 | 2017 | 8470 | 0.050 |
Why?
|
Surgical Flaps | 2 | 2020 | 1671 | 0.050 |
Why?
|
Radiation Protection | 2 | 2003 | 424 | 0.050 |
Why?
|
Hair Follicle | 1 | 2004 | 211 | 0.050 |
Why?
|
Tibia | 1 | 2008 | 1069 | 0.050 |
Why?
|
Radioisotope Teletherapy | 1 | 1982 | 15 | 0.050 |
Why?
|
Vitamin E | 1 | 2007 | 871 | 0.050 |
Why?
|
DNA Repair | 1 | 2011 | 2044 | 0.050 |
Why?
|
Immunotherapy | 1 | 2018 | 4649 | 0.050 |
Why?
|
Myelodysplastic Syndromes | 1 | 2012 | 1394 | 0.050 |
Why?
|
Poisson Distribution | 2 | 2008 | 504 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4509 | 0.050 |
Why?
|
X-Rays | 2 | 1995 | 307 | 0.050 |
Why?
|
Linear Models | 3 | 2018 | 5871 | 0.050 |
Why?
|
Radiation Effects | 1 | 2001 | 69 | 0.050 |
Why?
|
Patient Advocacy | 1 | 2024 | 360 | 0.050 |
Why?
|
Genome, Human | 1 | 2014 | 4423 | 0.050 |
Why?
|
Brain Stem | 2 | 2020 | 858 | 0.050 |
Why?
|
Orchiectomy | 1 | 2023 | 463 | 0.050 |
Why?
|
Neoplasm Proteins | 2 | 2011 | 3611 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 5 | 2016 | 20555 | 0.050 |
Why?
|
Heart | 1 | 2014 | 4405 | 0.050 |
Why?
|
ROC Curve | 3 | 2021 | 3572 | 0.050 |
Why?
|
Calibration | 1 | 2004 | 818 | 0.050 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2005 | 621 | 0.050 |
Why?
|
Cyclodextrins | 1 | 2001 | 66 | 0.050 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2015 | 2241 | 0.050 |
Why?
|
Cross-Sectional Studies | 5 | 2022 | 26108 | 0.050 |
Why?
|
Patient Care Team | 1 | 2012 | 2523 | 0.050 |
Why?
|
Cleavage Stage, Ovum | 1 | 1981 | 44 | 0.050 |
Why?
|
Neurosurgical Procedures | 3 | 2017 | 2071 | 0.050 |
Why?
|
Quality Control | 3 | 2012 | 835 | 0.050 |
Why?
|
Fertilization in Vitro | 2 | 1985 | 1292 | 0.050 |
Why?
|
Data Interpretation, Statistical | 2 | 2008 | 2691 | 0.050 |
Why?
|
Portal Vein | 1 | 2023 | 431 | 0.040 |
Why?
|
Implant Capsular Contracture | 1 | 2020 | 23 | 0.040 |
Why?
|
Serum Albumin, Bovine | 1 | 2001 | 322 | 0.040 |
Why?
|
Skull Base | 1 | 2023 | 292 | 0.040 |
Why?
|
Sexual Dysfunction, Physiological | 2 | 2016 | 357 | 0.040 |
Why?
|
Fat Necrosis | 1 | 2020 | 60 | 0.040 |
Why?
|
Medical Errors | 1 | 2008 | 1260 | 0.040 |
Why?
|
Medicine | 1 | 2008 | 940 | 0.040 |
Why?
|
Seroma | 1 | 2020 | 75 | 0.040 |
Why?
|
Arm | 2 | 2013 | 590 | 0.040 |
Why?
|
Alopecia | 1 | 2004 | 411 | 0.040 |
Why?
|
Technology, Radiologic | 2 | 1995 | 160 | 0.040 |
Why?
|
Embryonic Development | 2 | 2001 | 720 | 0.040 |
Why?
|
Radiography | 4 | 2014 | 6966 | 0.040 |
Why?
|
Natural Language Processing | 1 | 2008 | 1162 | 0.040 |
Why?
|
Evaluation Studies as Topic | 2 | 1993 | 1626 | 0.040 |
Why?
|
Nuclear Proteins | 2 | 2011 | 5794 | 0.040 |
Why?
|
Mice | 14 | 2023 | 81474 | 0.040 |
Why?
|
Decision Support Techniques | 1 | 2010 | 1998 | 0.040 |
Why?
|
Intestinal Diseases | 2 | 2016 | 504 | 0.040 |
Why?
|
World Health Organization | 2 | 2015 | 1320 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2023 | 559 | 0.040 |
Why?
|
Blood Loss, Surgical | 1 | 2023 | 636 | 0.040 |
Why?
|
Kidney | 1 | 2014 | 7049 | 0.040 |
Why?
|
Piperazines | 2 | 2020 | 2519 | 0.040 |
Why?
|
Skin | 3 | 2023 | 4482 | 0.040 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2001 | 353 | 0.040 |
Why?
|
Models, Statistical | 2 | 2007 | 5078 | 0.040 |
Why?
|
Xenopus Proteins | 1 | 2001 | 434 | 0.040 |
Why?
|
Genotype | 3 | 2021 | 12982 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2016 | 2853 | 0.040 |
Why?
|
Evidence-Based Practice | 1 | 2022 | 495 | 0.040 |
Why?
|
Thyroid Function Tests | 1 | 2019 | 289 | 0.040 |
Why?
|
Chimera | 1 | 1979 | 453 | 0.040 |
Why?
|
Artificial Intelligence | 2 | 2008 | 2578 | 0.040 |
Why?
|
Neurilemmoma | 1 | 2003 | 525 | 0.040 |
Why?
|
Hydrogen Peroxide | 1 | 2001 | 728 | 0.040 |
Why?
|
Cultural Diversity | 1 | 2021 | 368 | 0.040 |
Why?
|
Demography | 1 | 2022 | 1648 | 0.040 |
Why?
|
Phthalazines | 1 | 2020 | 382 | 0.040 |
Why?
|
United States | 7 | 2022 | 72317 | 0.040 |
Why?
|
Growth Disorders | 1 | 2022 | 653 | 0.040 |
Why?
|
CA-19-9 Antigen | 1 | 2017 | 106 | 0.040 |
Why?
|
Deoxycytidine | 2 | 2012 | 875 | 0.040 |
Why?
|
Animals | 19 | 2023 | 168388 | 0.040 |
Why?
|
Mitotic Index | 1 | 2017 | 161 | 0.040 |
Why?
|
Reference Values | 3 | 2009 | 4921 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2021 | 8527 | 0.040 |
Why?
|
Cell Division | 3 | 1997 | 4466 | 0.030 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2019 | 290 | 0.030 |
Why?
|
Glucose | 2 | 2013 | 4345 | 0.030 |
Why?
|
Spinal Cord Injuries | 2 | 2001 | 925 | 0.030 |
Why?
|
Biomedical Research | 2 | 2009 | 3429 | 0.030 |
Why?
|
Physicians | 2 | 2014 | 4591 | 0.030 |
Why?
|
Societies, Medical | 1 | 2008 | 3905 | 0.030 |
Why?
|
Mice, Inbred C3H | 2 | 2008 | 915 | 0.030 |
Why?
|
Career Mobility | 1 | 2018 | 259 | 0.030 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2012 | 3613 | 0.030 |
Why?
|
Rectum | 2 | 2002 | 892 | 0.030 |
Why?
|
Switzerland | 1 | 2016 | 324 | 0.030 |
Why?
|
Endocrine System Diseases | 1 | 2018 | 249 | 0.030 |
Why?
|
Brain Edema | 1 | 2020 | 604 | 0.030 |
Why?
|
Cell Line, Tumor | 4 | 2020 | 16966 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 628 | 0.030 |
Why?
|
DNA Methylation | 1 | 2010 | 4383 | 0.030 |
Why?
|
Growth | 2 | 2014 | 365 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2013 | 5334 | 0.030 |
Why?
|
Electrons | 1 | 2017 | 265 | 0.030 |
Why?
|
Lung | 3 | 2005 | 9994 | 0.030 |
Why?
|
Preoperative Care | 2 | 2017 | 2242 | 0.030 |
Why?
|
Cholelithiasis | 1 | 2017 | 407 | 0.030 |
Why?
|
Confidence Intervals | 2 | 2014 | 2927 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2015 | 3777 | 0.030 |
Why?
|
Rectal Diseases | 1 | 1996 | 143 | 0.030 |
Why?
|
Gene Amplification | 1 | 2019 | 1086 | 0.030 |
Why?
|
Thorax | 1 | 2018 | 555 | 0.030 |
Why?
|
Reproducibility of Results | 5 | 2010 | 20092 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2020 | 5297 | 0.030 |
Why?
|
Logistic Models | 4 | 2014 | 13251 | 0.030 |
Why?
|
Cluster Analysis | 2 | 2014 | 2712 | 0.030 |
Why?
|
Chromosome Aberrations | 1 | 1981 | 1771 | 0.030 |
Why?
|
Brain Diseases | 1 | 2003 | 1545 | 0.030 |
Why?
|
Anti-Infective Agents | 1 | 2001 | 984 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2011 | 11900 | 0.030 |
Why?
|
Travel | 1 | 2019 | 796 | 0.030 |
Why?
|
Signal Transduction | 2 | 2014 | 23427 | 0.030 |
Why?
|
Cytodiagnosis | 1 | 2017 | 447 | 0.030 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2020 | 946 | 0.030 |
Why?
|
Universities | 1 | 2018 | 994 | 0.030 |
Why?
|
Mentors | 1 | 2018 | 660 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2015 | 678 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2021 | 4850 | 0.030 |
Why?
|
Intraoperative Care | 1 | 2017 | 766 | 0.030 |
Why?
|
Infant | 3 | 2023 | 36202 | 0.030 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7389 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2013 | 5247 | 0.030 |
Why?
|
Pilot Projects | 2 | 2021 | 8632 | 0.030 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2013 | 296 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 15879 | 0.020 |
Why?
|
Cell Proliferation | 3 | 2017 | 10431 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2020 | 4108 | 0.020 |
Why?
|
Headache Disorders, Secondary | 1 | 2011 | 34 | 0.020 |
Why?
|
Acromegaly | 1 | 2014 | 310 | 0.020 |
Why?
|
Hydronephrosis | 1 | 2013 | 271 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 5 | 2018 | 36430 | 0.020 |
Why?
|
Oxygen | 1 | 2023 | 4227 | 0.020 |
Why?
|
Mice, Inbred CBA | 1 | 1992 | 436 | 0.020 |
Why?
|
Seminal Vesicles | 1 | 2011 | 103 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2019 | 1519 | 0.020 |
Why?
|
Rupture, Spontaneous | 1 | 2011 | 362 | 0.020 |
Why?
|
Surgical Wound Infection | 1 | 2020 | 1525 | 0.020 |
Why?
|
Marital Status | 1 | 2012 | 426 | 0.020 |
Why?
|
Thyrotropin | 1 | 2014 | 835 | 0.020 |
Why?
|
Sphenoid Bone | 1 | 1992 | 177 | 0.020 |
Why?
|
Odds Ratio | 2 | 2014 | 9639 | 0.020 |
Why?
|
Cell Migration Assays | 1 | 2010 | 22 | 0.020 |
Why?
|
Culture Techniques | 2 | 2001 | 531 | 0.020 |
Why?
|
Fast Neutrons | 1 | 2010 | 18 | 0.020 |
Why?
|
Carboplatin | 1 | 2013 | 794 | 0.020 |
Why?
|
Radiobiology | 2 | 2002 | 90 | 0.020 |
Why?
|
DNA-Binding Proteins | 2 | 2022 | 9605 | 0.020 |
Why?
|
Retinal Detachment | 1 | 2014 | 428 | 0.020 |
Why?
|
Inverted Repeat Sequences | 1 | 2010 | 60 | 0.020 |
Why?
|
Unnecessary Procedures | 1 | 2013 | 415 | 0.020 |
Why?
|
Pneumonia | 1 | 2001 | 2140 | 0.020 |
Why?
|
Duodenal Neoplasms | 1 | 2010 | 115 | 0.020 |
Why?
|
Protein Array Analysis | 1 | 2011 | 400 | 0.020 |
Why?
|
Wound Healing | 1 | 2001 | 2802 | 0.020 |
Why?
|
Meiosis | 1 | 1992 | 328 | 0.020 |
Why?
|
Palliative Care | 2 | 2011 | 3592 | 0.020 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2011 | 426 | 0.020 |
Why?
|
Creatinine | 1 | 2015 | 1899 | 0.020 |
Why?
|
Predictive Value of Tests | 3 | 2012 | 15262 | 0.020 |
Why?
|
Retreatment | 1 | 2011 | 598 | 0.020 |
Why?
|
British Columbia | 1 | 2010 | 241 | 0.020 |
Why?
|
Intraoperative Period | 1 | 2010 | 511 | 0.020 |
Why?
|
Pain Measurement | 1 | 2019 | 3552 | 0.020 |
Why?
|
Dogs | 2 | 2007 | 3839 | 0.020 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2010 | 197 | 0.020 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 1996 | 1116 | 0.020 |
Why?
|
Antineoplastic Agents | 3 | 2020 | 13635 | 0.020 |
Why?
|
Sampling Studies | 1 | 1990 | 615 | 0.020 |
Why?
|
Sensitivity and Specificity | 3 | 2013 | 14665 | 0.020 |
Why?
|
Inpatients | 1 | 2020 | 2548 | 0.020 |
Why?
|
Observation | 1 | 2010 | 310 | 0.020 |
Why?
|
Area Under Curve | 1 | 2013 | 1633 | 0.020 |
Why?
|
Basal Ganglia | 1 | 2011 | 554 | 0.020 |
Why?
|
History, 20th Century | 1 | 2016 | 2770 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2018 | 2423 | 0.020 |
Why?
|
Case-Control Studies | 3 | 2014 | 22124 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2012 | 643 | 0.020 |
Why?
|
Memory | 1 | 2018 | 2187 | 0.020 |
Why?
|
Glioblastoma | 1 | 2003 | 3482 | 0.020 |
Why?
|
Organ Specificity | 2 | 2003 | 1967 | 0.020 |
Why?
|
Databases as Topic | 1 | 2010 | 473 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3638 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 3200 | 0.020 |
Why?
|
Pyridines | 1 | 2019 | 2870 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2007 | 10764 | 0.020 |
Why?
|
Normal Distribution | 1 | 2007 | 272 | 0.020 |
Why?
|
Nuclear Warfare | 1 | 2007 | 30 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2010 | 696 | 0.020 |
Why?
|
Stem Cells | 1 | 2000 | 3521 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2015 | 2176 | 0.020 |
Why?
|
Radiation-Protective Agents | 1 | 2007 | 88 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2016 | 10203 | 0.020 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2011 | 422 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1742 | 0.020 |
Why?
|
Mediastinum | 1 | 2007 | 267 | 0.020 |
Why?
|
Acute Disease | 1 | 2017 | 7238 | 0.020 |
Why?
|
Mass Screening | 1 | 2022 | 5428 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 1336 | 0.020 |
Why?
|
Haplorhini | 1 | 2007 | 529 | 0.020 |
Why?
|
Steroids | 1 | 2011 | 928 | 0.020 |
Why?
|
Intracranial Hemorrhages | 1 | 2011 | 822 | 0.020 |
Why?
|
Random Allocation | 1 | 1990 | 2389 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2015 | 2650 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 3878 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2013 | 942 | 0.020 |
Why?
|
Sperm-Ovum Interactions | 1 | 1985 | 23 | 0.020 |
Why?
|
Cochlea | 1 | 2012 | 845 | 0.020 |
Why?
|
Pregnancy | 4 | 2017 | 29858 | 0.020 |
Why?
|
Benchmarking | 1 | 2012 | 1045 | 0.020 |
Why?
|
Remission Induction | 1 | 2011 | 2395 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2018 | 7045 | 0.020 |
Why?
|
Anxiety | 1 | 2019 | 4571 | 0.010 |
Why?
|
Mice, SCID | 1 | 2010 | 2625 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2011 | 4022 | 0.010 |
Why?
|
Visual Acuity | 1 | 2014 | 2671 | 0.010 |
Why?
|
Stroke Volume | 1 | 2018 | 5497 | 0.010 |
Why?
|
Primates | 1 | 2007 | 524 | 0.010 |
Why?
|
Maximum Allowable Concentration | 1 | 2003 | 63 | 0.010 |
Why?
|
Cause of Death | 1 | 2014 | 3685 | 0.010 |
Why?
|
Dexamethasone | 1 | 2011 | 1946 | 0.010 |
Why?
|
Retina | 1 | 2014 | 2656 | 0.010 |
Why?
|
Body Burden | 1 | 2003 | 158 | 0.010 |
Why?
|
Coronary Vessels | 1 | 2014 | 3094 | 0.010 |
Why?
|
Sex Factors | 2 | 2012 | 10551 | 0.010 |
Why?
|
Reoperation | 1 | 2013 | 4302 | 0.010 |
Why?
|
Prostate | 1 | 2011 | 1770 | 0.010 |
Why?
|
Cerebral Hemorrhage | 1 | 2014 | 2656 | 0.010 |
Why?
|
Tumor Stem Cell Assay | 1 | 2002 | 115 | 0.010 |
Why?
|
Minicomputers | 1 | 1982 | 10 | 0.010 |
Why?
|
Gene Deletion | 1 | 2010 | 2667 | 0.010 |
Why?
|
Pattern Recognition, Automated | 1 | 2008 | 997 | 0.010 |
Why?
|
Mice, Inbred Strains | 1 | 1985 | 1759 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2018 | 14597 | 0.010 |
Why?
|
Heart Ventricles | 1 | 2014 | 3816 | 0.010 |
Why?
|
Rectus Abdominis | 1 | 2002 | 103 | 0.010 |
Why?
|
Magainins | 1 | 2001 | 2 | 0.010 |
Why?
|
Cell Cycle | 1 | 2010 | 2930 | 0.010 |
Why?
|
Self Report | 1 | 2013 | 3724 | 0.010 |
Why?
|
Immobilization | 1 | 2002 | 227 | 0.010 |
Why?
|
Registries | 1 | 2017 | 8223 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2011 | 2870 | 0.010 |
Why?
|
Radiation Injuries, Experimental | 1 | 2001 | 88 | 0.010 |
Why?
|
Liver | 1 | 2017 | 7531 | 0.010 |
Why?
|
Seizures | 1 | 2014 | 2956 | 0.010 |
Why?
|
Biopsy | 1 | 2012 | 6768 | 0.010 |
Why?
|
Cognition | 1 | 2018 | 6987 | 0.010 |
Why?
|
Macaca mulatta | 1 | 2007 | 2332 | 0.010 |
Why?
|
Breast | 1 | 2009 | 1966 | 0.010 |
Why?
|
Replantation | 1 | 1981 | 145 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2006 | 3419 | 0.010 |
Why?
|
Tomography, Emission-Computed | 1 | 2002 | 1122 | 0.010 |
Why?
|
Photometry | 1 | 1979 | 58 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 12949 | 0.010 |
Why?
|
Phantoms, Imaging | 1 | 2007 | 2524 | 0.010 |
Why?
|
Hair Color | 1 | 1979 | 131 | 0.010 |
Why?
|
Motion | 1 | 2002 | 779 | 0.010 |
Why?
|
Statistics as Topic | 1 | 2005 | 2358 | 0.010 |
Why?
|
Prevalence | 1 | 2015 | 15719 | 0.010 |
Why?
|
Pediatrics | 1 | 2013 | 3594 | 0.010 |
Why?
|
Embryo Transfer | 1 | 1981 | 522 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10498 | 0.010 |
Why?
|
Computer Simulation | 1 | 2011 | 6236 | 0.010 |
Why?
|
Bacteria | 1 | 2008 | 2216 | 0.010 |
Why?
|
Meta-Analysis as Topic | 1 | 2002 | 1376 | 0.010 |
Why?
|
Superovulation | 1 | 1976 | 11 | 0.010 |
Why?
|
Drug Synergism | 1 | 2001 | 1757 | 0.010 |
Why?
|
Ultrasonography | 1 | 2010 | 5970 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2007 | 2821 | 0.010 |
Why?
|
Phenotype | 1 | 2014 | 16603 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2001 | 2498 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2007 | 2644 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2001 | 2218 | 0.010 |
Why?
|
Diploidy | 1 | 1975 | 132 | 0.010 |
Why?
|
Fibrosis | 1 | 2002 | 2048 | 0.010 |
Why?
|
Sex Chromosomes | 1 | 1975 | 102 | 0.010 |
Why?
|
Doxorubicin | 1 | 2001 | 2215 | 0.010 |
Why?
|
Models, Animal | 1 | 2001 | 2112 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2011 | 7852 | 0.010 |
Why?
|
Terminology as Topic | 1 | 2002 | 1535 | 0.010 |
Why?
|
Dietary Supplements | 1 | 2007 | 3413 | 0.010 |
Why?
|
Kinetics | 1 | 2001 | 6374 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 1992 | 22154 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2010 | 4812 | 0.010 |
Why?
|
Spermatozoa | 1 | 1976 | 630 | 0.010 |
Why?
|
Fertility | 1 | 1976 | 771 | 0.010 |
Why?
|
Cornea | 1 | 1979 | 1332 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2007 | 18962 | 0.010 |
Why?
|
Apoptosis | 1 | 2007 | 9474 | 0.010 |
Why?
|
Mitosis | 1 | 1975 | 1186 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 1975 | 4810 | 0.000 |
Why?
|
Intestinal Mucosa | 1 | 1996 | 3027 | 0.000 |
Why?
|
Rats | 1 | 2001 | 23729 | 0.000 |
Why?
|
Inflammation | 1 | 2001 | 10760 | 0.000 |
Why?
|